In this episode of 340Banter, we sit down with Christina Harbison, Senior Clinical Pharmacist at Prism Health North Texas, to discuss how the organization grew its long-acting injectable (LAI) program from 18 patients to approximately 700.

Christina shares how Prism Health North Texas has navigated medication acquisition, prescription and medical benefits, buy-and-bill, prior authorizations, and payer requirements while expanding access to long-acting injectable options for HIV treatment and prevention.

We also discuss the operational aspects of building an LAI program, including securing organizational buy-in, developing the right staffing model, verifying coverage prior to administration, and involving pharmacists in medication management and patient counseling.

For health centers considering long-acting injectables or working to expand an existing program, Christina offers practical advice based on Prism Health North Texas' experience: start slowly, understand the financial risks, establish reliable processes, and ensure patients can maintain access to treatment over time.

Let’s connect:

In this episode of 340Banter, we sit down with Angela Sorber, Director of Pharmacy Service Line at Nevada Health Centers, to discuss the realities of managing 340B pharmacy operations across multiple in-house pharmacy locations.

Angela shares how her team adapts to the unique needs of different patient populations while maintaining consistent operations across the organization. We discuss the importance of empowering local pharmacy leaders, using data to guide decision-making, and fostering strong communication across pharmacy teams. She also offers practical insights into balancing operational efficiency with patient access to medications.

Whether you're managing one pharmacy or multiple locations, this conversation offers valuable takeaways on building scalable processes, supporting pharmacy teams, and delivering high-quality patient care.

Let's connect:

In this episode of 340Banter, we break down one of the biggest operational challenges facing health centers today: documenting clinic-administered drugs.

For many organizations, paper logs and spreadsheets are no longer enough to keep up with evolving manufacturer requirements. As the industry moves toward rebate models and medical claims data submissions, gaps in documentation and billing could put 340B savings at risk.

We discuss what these changes mean, the technology and workflow improvements health centers should be considering now, and why high-value medications like long-acting injectables and HIV treatments deserve special attention.

If your organization is still relying on manual processes, this conversation will help you understand what's changing and how to prepare before these requirements become unavoidable. 

Let’s connect:

How often do HRSA Operational Site Visits (OSVs) occur, and what exactly are reviewers looking for during these important compliance assessments?

In this episode of 340Banter, Chelsea Violette and Logan Yoho discuss recent updates to HRSA's Operational Site Visit (OSV) Protocol and how the changes help clarify expectations for health centers navigating compliance requirements.

A key focus of the conversation is the Sliding Fee Discount Program (SFDP), an area that has historically created confusion during site visits. Chelsea and Logan break down the latest protocol updates, explain what has changed, and discuss how health centers can better prepare for OSV reviews by understanding HRSA's current expectations.

Whether you're a CEO, COO, compliance officer, operations leader, or health center administrator, this episode provides practical insights to help your organization stay informed and prepared for HRSA oversight activities.

Let’s connect:

What do all those 340B financial reports actually mean, and how can organizations make sense of them when every vendor seems to report data differently?

In this episode of 340Banter, Chelsea Violette and Logan Yoho sit down with Michael Gonzalez, Founder of FQHC 340B Compliance, to unpack one of the biggest operational challenges facing 340B Programs today: navigating non-standardized financial reporting across TPAs, pharmacy platforms, and vendor systems.

From confusing terminology and inconsistent report formats to understanding what metrics truly matter, this conversation explores how covered entities can better track the financial performance and overall health of their 340B Program. Michael shares practical strategies for improving visibility into savings, identifying reporting gaps, monitoring trends over time, and creating a more proactive approach to financial oversight and compliance.

Whether you're a 340B coordinator, CFO, pharmacy leader, or compliance professional, this episode delivers valuable insight into how organizations can strengthen financial monitoring, ask better questions of their vendors, and maintain a clearer pulse on the sustainability and performance of their 340B operations.

Let’s connect: https://www.fqhc340b.com/ | [email protected]

What exactly is an Annual Single Audit, and why does it matter for organizations participating in the 340B Drug Pricing Program? In this episode of 340Banter, Chelsea Violette and Logan Yoho sit down with Michael Gonzalez, Founder of FQHC 340B Compliance, to break down the essentials of the Single Audit process and its critical connection to pharmacy operations within 340B Programs.

Whether you're a compliance officer, healthcare administrator, or pharmacy leader, this episode delivers practical insights into how federal audit requirements impact covered entities, funding accountability, and 340B Program integrity. Learn how Single Audits evaluate financial controls, ensure compliance with federal regulations, and influence pharmacy partnerships and contract pharmacy oversight.

Donavan received his Bachelor’s degree in pharmacy from the University of Utah College of Pharmacy in 1995. His past work experience includes being a retail pharmacist at Albertsons, a Director of Pharmacy at Gunnison Valley Hospital, and a Director of Pharmacy at Central Valley Medical Center. While at Gunnison Valley Hospital, he sat on the Pharmacy and Therapeutics committee and was an active member of the Gunnison Valley Hospice program. In addition, Donavan was an adjunct faculty member at the Snow College Richfield Allied Health department for 6 years, where he developed and taught the pharmacy technician program. In 2005, he started his current position as the Director of Pharmacy at the Wayne Community Health Center in Bicknell, Utah. In 2007, Donavan received the Stephen D. Ratcliff award from the Association of Utah Community Health Centers in recognition of his efforts as a positive visionary leader. From spring 2012 to 2014, Donavan served 2 years as a 340B Peer-to-Peer Mentor with the American Pharmacists Association Federal Contracts and Grants. During this time, he received the Peer All-Star Award and Peer Spirit Award. Donavan sits on the Apexus 340B Prime Vendor Program Advisory Council for Federally Qualified Health Centers. As a Director of Pharmacy, Donavan has helped spearhead the chronic pain management program at Wayne Community Health Center. This program received recognition in 2010 from the Sevier Valley Substance Abuse Coalition for its outstanding efforts in the fight against prescription drug abuse. He sits on the P&T committee and is an active member of the clinical multidisciplinary team and the Emergency room team. During his employment with Wayne Community Health Center, he has helped implement and manage the acute coronary treatment program, including the usage of thrombolytics in a rural clinic 60 miles away from the nearest hospital and 160 miles from the nearest acute cardiac center. In 2018 and 2019, Donavan and Zackery Taylor, PharmD. Wayne Community Health Center became the first open-door telepharmacy-retail pharmacy for a remote dispensing site located in Green River, Utah.

On this episode of 340Banter, Donovan Smith, CEO of Wayne Community Health Centers, details the real-world impact of the IRA’s Maximum Fair Price (MFP) implementation. He explains how claims are being misattributed to 340B, the challenges of a dual inventory model in a remote pharmacy, the financial strain from denied rebates and low dispensing fees, and the risks to patient access. Donovan also discusses advocacy efforts and potential fixes to make the process fairer for small, rural safety-net providers.

In this episode, we explore a powerful and timely topic: How to reteach yourself how to learn. Whether you’re returning to school, starting a new career, rebuilding confidence, or simply feeling stuck, learning as an adult can feel very different than it did before. The good news? Learning is a skill, and it can be rebuilt. This conversation dives into the mindset shifts, habits, and strategies that help you become a better learner again, especially in a world full of distractions, burnout, and information overload. If you’ve ever thought, “I don’t know how to learn anymore,” this episode is for you. 👉 Subscribe for more conversations on personal growth, mindset, productivity, and lifelong learning.

In this episode of the 340Banter Podcast, co-hosts Chelsea Violette and Logan Yoho take a closer look at MFP Drugs, the first prescription medications selected for Maximum Fair Price (MFP) under Medicare’s new drug pricing authority.